Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 29INDUSTRY 17OTHER_GOV 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

sargramostim 3Methods 3Granulocyte-Macrophage Colony-Stimulating Factor 3Exercise 3Colonoscopy 3Prednisone 2Palliative Care 2Leuprolide 2Golytely 2Gelatin 2Decision Support Techniques 2Collagenases 2Clofarabine 2Cholecalciferol 2Calcitriol 2ADI PEG20 2talabostat 1sulforaphane 1apalutamide 1abiraterone 1Yoga 1Water 1Tretinoin 1Topotecan 1Thioctic Acid 1Tablets 1Surgical Instruments 1Streptozocin 1Standard of Care 1Social Work 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × FED × Tablets × Clear all
NCT00086203 2015-03-25

Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)

FDA Office of Orphan Products Development

Phase 2 Completed
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡